1. Home
  2. EQ

EQ

Equillium Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Founded: 2017 Country:
United States
United States
Employees: N/A City: LA JOLLA
Market Cap: 74.4M IPO Year: 2018
Target Price: $3.90 AVG Volume (30 days): 377.9K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.38 EPS Growth: N/A
52 Week Low/High: $0.45 - $3.25 Next Earning Date: 05-09-2024
Revenue: $36,084,000 Revenue Growth: 128.97%
Revenue Growth (this year): 6.19% Revenue Growth (next year): 47.85%

Share on Social Networks: